<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00161707</url>
  </required_header>
  <id_info>
    <org_study_id>410103</org_study_id>
    <nct_id>NCT00161707</nct_id>
  </id_info>
  <brief_title>Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency</brief_title>
  <official_title>Phase I Safety Investigation of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arriva Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      The purpose of this randomized, double-blind, placebo-controlled study is to evaluate the&#xD;
      short-term safety of inhaled recombinant alpha 1-antitrypsin (rAAT) in subjects with alpha&#xD;
      1-antitrypsin deficiency. The subjects are randomized to receive placebo or one of 4 doses of&#xD;
      rAAT. The 4 doses are tested in a consecutive manner from lowest to highest.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 7, 2003</start_date>
  <completion_date type="Actual">October 1, 2003</completion_date>
  <primary_completion_date type="Actual">October 1, 2003</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who develop antibodies to Recombinant Alpha 1-Antitrypsin (rAAT)</measure>
    <time_frame>6 weeks after the first inhalation of study drug</time_frame>
  </primary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Alpha1-antitrypsin Deficiency</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aerosolized, Recombinant Alpha 1-Antitrypsin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 18 years of age or older&#xD;
&#xD;
          -  Endogenous plasma AAT levels &lt; 11 µM (&lt; 80 mg/dL)&#xD;
&#xD;
          -  Baseline forced expiratory volume at one second (FEV1) that is &gt;= 50% of predicted,&#xD;
             measured 30 minutes after a short-acting inhaled bronchodilator&#xD;
&#xD;
          -  Baseline arterial oxygen percent saturation (SaO2) within the normal limits for the&#xD;
             individual study site&#xD;
&#xD;
          -  For subjects receiving an inhaled corticosteroid, β-2 agonist (eg, albuterol via&#xD;
             metered dose inhaler [MDI]) or anticholinergic bronchodilator (eg, ipratropium&#xD;
             bromide), treatment on a stable dose for at least 14 days prior to randomization&#xD;
&#xD;
          -  If female of childbearing potential, negative urine pregnancy test within 3 days prior&#xD;
             to randomization and agreement to employ adequate birth control measures&#xD;
&#xD;
          -  No clinically significant abnormalities detected on a 12-lead electrocardiogram (ECG)&#xD;
             performed no more than 7 days prior to randomization&#xD;
&#xD;
          -  Baseline laboratory results, obtained no more than 7 days prior to randomization,&#xD;
             meeting the following criteria:&#xD;
&#xD;
          -  Serum aspartate transaminase (AST) and alanine transaminase (ALT) &lt;= 2 times upper&#xD;
             limit of normal range (ULN)&#xD;
&#xD;
          -  Serum total bilirubin &lt;= 2 times ULN&#xD;
&#xD;
          -  &lt; 2+ proteinuria on urine dipstick&#xD;
&#xD;
          -  Serum creatinine &lt;= 1.5 times ULN&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1500 cells/mm3&#xD;
&#xD;
          -  Hemoglobin &gt;= 10.0 g/dL&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm3&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant pulmonary impairment, other than emphysema and/or chronic&#xD;
             bronchitis&#xD;
&#xD;
          -  Clinically significant cardiac, hemostatic, or neurologic impairment, or other&#xD;
             significant medical condition that, in the opinion of the investigator, would affect&#xD;
             subject safety or compliance&#xD;
&#xD;
          -  Psychiatric or cognitive disturbance or illness, or recreational drug/alcohol use&#xD;
             that, in the opinion of the investigator, would affect subject safety or compliance&#xD;
&#xD;
          -  Acute exacerbation of emphysema (as defined in Section 8.5.10) within 28 days prior to&#xD;
             randomization&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Known history of allergy to yeast products&#xD;
&#xD;
          -  Medical history precluding the use of epinephrine or other rescue medication for&#xD;
             treatment of anaphylaxis&#xD;
&#xD;
          -  Use of antihistamines within 7 days prior to randomization&#xD;
&#xD;
          -  Use of oral steroids, beta-blockers, or tricyclic antidepressants within 28 days prior&#xD;
             to randomization&#xD;
&#xD;
          -  Use of another investigational drug or investigational device within 28 days prior to&#xD;
             randomization&#xD;
&#xD;
          -  Any upper or lower respiratory infection within 28 days prior to randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Jewish Medical and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shands Hospital at the University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation, Department of Pulmonary and Critical Care Medicine</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708-3154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
    <mesh_term>Protein C Inhibitor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

